• Little-known ASX share you should hold for 5 years: analyst

    Ask A Fund Manager

    In part 1 of our interview, Monash Investors co-founder and director Simon Shields showed us 2 quality ASX stocks with still-low PE ratios. Now in part 2, he reveals the fintech share that he’s proud to have bought at $5 then exited at $153.

    Overrated and underrated shares

    The Motley Fool: What’s your most underrated stock at the moment?

    Simon Shields: People Infrastructure Ltd (ASX: PPE) is the most underrated stock. [Shields discusses People Infrastructure in part 1 of the interview].

    MF: What do you think is the most overrated stock at the moment?

    SS: Now the most overrated stock is, sadly, I’m going to say, Flight Centre Travel Group Ltd (ASX: FLT) — because everybody loves Flight Centre as a business. It’s been around for a long time. In fact, it was a store rollout story in its day. It’s a great Australian business, it’s a global company. 

    But that drag it’s got from having those bricks-and-mortar stores, it’s just been a huge loser. From COVID it’s already had to do a couple of capital risings. With the lag that we’re seeing in the recovery, I dare say, it’s probably going to have to do another one.

    Capable people are giving it the benefit of doubt because, of course, when travel starts back, there’ll be a huge boom in travel, no question about that. But it keeps receding and that’s the problem.

    MF: Did you once hold it then exited, or have you never held it?

    SS: We’ve long and shorted the stock — and we’re currently short.

    MF: If the market closed tomorrow for 5 years, which stock would you want to hold?

    SS: Electro Optic Systems Holdings Ltd (ASX: EOS). It’s Australia’s probably major defence stock, and fantastic technology in laser targeting for use in space communications, tracking satellites, space junk, and by the military. 

    And it’s just got a very long pipeline of contracts that it’s going to be bidding on and almost certainly likely to win a very large percentage of those, given its leadership in those areas.

    MF: It’s been around for a while, hasn’t it?

    SS: It has. And so if you think, ‘Why might the market be closed for five years?’, well, I think a defence stock in that circumstance would go pretty well.

    Looking back

    MF: Which stock are you most proud of from a past purchase?

    SS: Afterpay Ltd (ASX: APT). We didn’t buy Afterpay in the IPO because we were concerned about this new product and the bad debts it could have. So we didn’t get into it until it got to $5.

    Of course, it listed at $1, so at $5 you’d think, ‘we’ve missed it’. But our valuation was much, much higher. And what was driving our valuation was, first of all, how we could see it was such an easy sell for the company. They had the metrics because it was all about online sales. They could increase the [merchant]’s online sales by 10% or 15%, and so it was such an easy thing for a merchant to adopt it.

    The second thing, we could see the behaviour by the customers that they would maybe use it once every 3 months in the first year, but in the second year they’d be using twice every 3 months. And by the time it got to the fourth year, they were using it over 20 times a year.

    Although we’d been buying and selling all the way through — we actually sold out our last shares at $153.

    What was really pleasing about that, we were very clear in what we thought each geographic region was worth. So Australia, we thought was worth $7, the United States we thought was worth $70, for example. 

    It was putting all those geographic regions together, got us to our price target. And when our price target was met, then we sold out.

    Just on the reason for that, it’s the great thing about doing that assessed valuation. When we sold at $150, we were getting paid for everything we thought Afterpay was going to do for the next 8 or 9 years. So there’s no point hanging around waiting for the next 8 or 9 years to see if it was going to do it because we’re getting paid for it.

    And that’s why we sold. That’s the whole theory behind the assessed valuation.

    MF: Is there a move that you regret from the past? For example, a missed opportunity or buying a stock at the wrong timing or price.

    SS: I regret not making a lot of money from Altium Limited (ASX: ALU).

    Altium was a stock that I first came across in the tech boom, in the late 1990s and knew the business really, really well then. It sort of drifted, actually, after the tech wreck and didn’t do all that well. 

    They remembered me too. I did a company visit with them and they were asking me what I thought of their business strategy. And I said, ‘Well, I think you should go to subscription rather than just sell upfront‘. And unbeknownst to me, they did that, and then the next thing I know, the stock’s taken off and I felt like I’d missed it. 

    And of course, I hadn’t missed it and it kept going. So that was my big regret.

    MF: How do you feel about Altium at the moment? It’s discounted from the highs of the past couple of years?

    SS: Yeah. So, I mean, look, it was interesting, during COVID they found that the sales fell back, and I just wondered to what extent the issues around China and Australia might be hampering their sales at the moment, it’s hard to tell. 

    Also, they’ve had to do a fair bit of discounting to try and meet their targets and that’s always a real red flag, so we’re wary of it at the moment.

    MF: Last thoughts?

    SS: Look, as investors, we’re dealing with uncertainty. And all we can try and do is secure the odds in our favour as much as possible. Even then, sometimes we won’t have good periods because it’s a question of ‘Are the opportunities there?’ 

    Generally, there’s always going to be some opportunities out there. [But] the other thing is, can we find them? Sometimes they’re easier to find, but other times there are less opportunities and they’re harder to find. 

    All I’d say is that nobody, I don’t think, is consistently just finding them all the time — but generally over time, you can see if somebody does a good job or not.

    The post Little-known ASX share you should hold for 5 years: analyst appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3gaMVRM

  • Amazon’s latest advertising move could fill a vacuum left by alphabet

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    Amazon (NASDAQ: AMZN) recently confirmed to advertising trade publication Digiday that it plans to launch its own third-party cookie tracker. The move could prove to be a significant boon for the company’s fast-growing digital advertising platform and comes after Alphabet‘s (NASDAQ: GOOG)(NASDAQ: GOOGL) decision to change the way that user data can be collected through its Chrome web browser. 

    Amazon’s upcoming identifier technology will be limited to the company’s advertising ecosystem, so it won’t be able to replace the breadth of tracking functionality being lost with Chrome. But the e-commerce and cloud computing company is rapidly gaining market share in the digital ad space, and supplying useful new tools should help it continue to gain ground. It’s unclear when Amazon’s advertising identifier might launch.  

    Alphabet’s leading positions in the browser, search, and mobile operating spaces have made the company a powerhouse in the digital ads market. But these strengths have also raised antitrust concerns, and the company is facing regulatory pressure in the U.S., the European Union, and other markets. It is changing its approach to cookie tracking in response to these conditions, and the shift could create opportunities for Amazon despite also creating some initial hurdles to clear. 

    Amazon’s advertising business still trails far behind Alphabet’s and Facebook‘s respective ventures, but the e-commerce giant is rapidly gaining ground in the territory and already ranks as the third-largest digital ads platform in the U.S. Advertising is shaping up to be a substantial growth driver for Amazon through the next decade and beyond, and the company’s market-leading e-commerce platform and analytics expertise have it in good position to continue quickly gaining market share. 

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

    The post Amazon’s latest advertising move could fill a vacuum left by alphabet appeared first on The Motley Fool Australia.

    This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.



    from The Motley Fool Australia https://ift.tt/3fLb3v7
  • Why has the Tesserent (ASX:TNT) share price dropped more than 50% in 2021?

    Tesserent Ltd (ASX: TNT) is the largest pure-play cybersecurity company listed on the ASX, but the Tesserent share price has been in decline of late. It’s shares have slumped from a 52-week high of 44 cents in January to today’s price of 21 cents. 

    This amounts to a drop of more than 50% and while the fall can’t be attributed to one factor, it is worth taking a closer look at the recent activities of the company.

    Acquisitions R Us

    In a 2020 interview with the Australian Financial Review (AFR), Tesserent chairman Geoff Lord believed the company would be able to generate 25% of the growth needed organically, while the remaining 75% would come through acquisitions. Previously, Lord was the founder of the successful tech business, UXC.

    True to his word, by December 2020, Tesserent had made five acquisitions including Ludus, Airloom, Seer, iQ3 and New Zealand’s Lateral Security. Additionally, Tesserent spent about $22 million on purchasing the managed security services business of Secure Logic.

    Last month, Tesserent made further investments in cybersecurity startups TrustGrid and AttackBound. The purchase marks Tesserent’s intention to enter into a software-as-a-service (SaaS) based technology offering. According to the company’s announcement, the purchase was executed through a mix of $1.5 million in cash and $1.5 million in shares at a purchase price of $0.2345 per share.  

    In most instances, debt is the price for growth, especially via an acquisition strategy. Consequently, as at the end of December 2020, Tesserent had $9.91 million of debt, up from$3.45 million a year ago.

    Acquisitions are known to spook some investors. As with Tesserent, the nature of an acquisition transaction, is that the acquiring firm either pays in cash, and or issues equity, this dilutes the value of the existing shares.

    …but everything is tracking nicely

    Despite the drop in the Tesserent share price, the company’s latest quarterly report highlights an increase in earnings before interest, tax, depreciation and amortisation (EBITDA) to $1.7 million for the quarter. It also reported a 21.4% EBITDA increase quarter on quarter. The report has Tesserent targeting a $150 million turnover by 30 June. 

    According to the business, it’s well placed to deliver on its acquisition strategy growth plans, with $7.7 million in available cash at the end of March. The report also states that it plans to increase its market cap from $200 million to $300 million-plus and become profitable by next year. 

    Government and corporate tailwinds

    Tesserent is also riding some government and corporate tailwinds.

    Cyber ransomware attacks have become the grim reaper of Australian business. In March this year, the AFR reported more than half of Australian businesses were hit by attacks on their computer systems. Apart from disruption and repair costs to systems, 54% of businesses paid their attackers, but a quarter of those did not get their data returned.

    In May 2021, ANZ institutional banking boss Mark Whelan told an annual banking summit (as quoted by the AFR): “The number of attacks had escalated during the pandemic to the point where it was receiving 8 to 10 million attacks a month”.

    Tailwinds are coming from the government as well. In the recent 2021 budget, Prime Minister Scott Morrison announced $1.67 billion in existing defence funding would be spent over the next decade to boost cybersecurity capabilities.

    It is also now mandatory for enterprises with $3 million of revenue or more to report cybersecurity breaches. The Australian Cyber Security Centre is projecting the cybersecurity industry to grow from $5.1 billion in 2019 to $7.6 billion in 2024. 

    Additionally, a recent PWC survey found that 40% of Australian businesses plan to increase their cybersecurity resources over the next year.

    According to Tesserent, it currently partners with 43 out of the top 100 companies on the ASX.

    Tesserent share price snapshot

    The Tesserent share price has dropped, but investors will no doubt be hoping it is on track to deliver on growth projections.

    In the last 12 months, the Tesserent share price has increased by 215%, outperforming the S&P/ASX 200 Index (ASX: XJO) which delivered a 21.5% increase.

    The post Why has the Tesserent (ASX:TNT) share price dropped more than 50% in 2021? appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3phmYnn

  • Is the CSL (ASX:CSL) share price good value today?

    The CSL Limited (ASX: CSL) share price hasn’t been getting much love from investors over the last 12 months.

    During this time, the biotherapeutics giant’s shares are trading broadly flat. This compares to a 21% gain by the S&P/ASX 200 Index (ASX: XJO).

    Is this a buying opportunity?

    CSL has been operating for over a century. It was founded in 1916 with the aim of servicing the needs of a nation isolated by war. Today, the company is a global giant with a portfolio of therapies and vaccines saving countless lives across the world.

    One of the keys to its success has been the company’s high level of investment in research and development. Every year CSL invests approximately 10% to 12% of its sales revenue back into its these activities. This has helped ensure that CSL is at the forefront of innovation and has a pipeline of potentially lucrative products.

    Unfortunately, the company has been struggling with plasma collections during the pandemic. This is because lockdowns, social distancing, and government stimulus payments have all had negative impacts on donations.

    Given that plasma is a core ingredient in many of its therapies, lower collections is bad news for CSL and is expected to drive costs higher. However, the good news here is that this headwind is only expected to be short-lived. In fact, recent data reveals that collections are already rebounding strongly and have been tipped to reach pre-COVID levels later this year.

    In light of this, with the CSL share price still trading notably lower than its 52-week high, now could be an opportune time to make a long term investment.

    Who rates the CSL share price as a buy?

    One broker that thinks the CSL share price is in the buy zone is Citi.

    It recently retained its buy rating and $310.00 price target. The broker believes that recent industry trends are looking favourable for the company.

    Citi explained: “Over the last few weeks, most of CSL’s listed competitors have reported results. When we look at the data overall, it points to an improvement in the rate of plasma collection in April, which has been the main impediment to growth throughout the pandemic.”

    “It also points to continued strong demand for the end-product, in particular IG. Overall this gives us confidence in our Buy call on CSL, although we are yet to see the earnings trough for the company which will occur in FY22 given the long lead times from plasma collection to sale.”

    The post Is the CSL (ASX:CSL) share price good value today? appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uJ54LG

  • 2 mid cap ASX shares growing strongly

    If you are interested in investing in some promising mid cap shares, then you may want to take a look at the two listed below.

    Both are growing at a strong rate and have a lot of potential. Here’s what you need to know about these ASX shares:

    Collins Foods Ltd (ASX: CKF)

    Collins Foods is a leading quick service restaurant operator with a focus on KFC restaurants.

    At present, the company operates 251 KFC restaurants throughout Australia. These are predominantly in the Queensland market, with 158 restaurants in the state. Collins Foods also has a growing European footprint, with 17 KFC restaurants in Germany and 28 in the Netherlands, and 16 Taco Bell restaurants throughout Australia.

    It has been a positive performer during the pandemic. During the first half of FY 2021, Collins Foods reported an 11.3% increase in revenue to $499.6 million. And thanks to margin expansion, the company’s underlying net profit after tax came in 15.1% higher at $27.5 million.

    Pleasingly, Collins Foods appears well-placed for growth in the future thanks to its store expansion opportunities. This is particularly the case for its KFC restaurants in the underpenetrated European market. It also has the option of adding to its portfolio of brands through acquisitions, developments, or agreements. 

    Hipages Group Holdings Ltd (ASX: HPG)

    Another mid cap ASX share to take a look at is Hipages. It is a leading Australia-based online platform and software as a service (SaaS) provider.

    Hipages’ focus is on connecting tradies with residential and commercial consumers. At the last count, over three million Australians had used its popular platform. This provided work to over 34,000 tradie businesses that are subscribed to the platform.

    But there’s more to the company than that. It also provides businesses with its Call of Service job management software. This has been designed to improve tradies’ productivity by streamlining their workflow and taking away the stress of admin.

    At present the company is capturing approximately 5% of total industry advertising spend, but has been tipped to grow its market share materially in the future. For example, a recent note out of Goldman Sachs reveals that its analysts see scope for Hipages to capture upwards of 40% to 60% in the future as its builds out its ecosystem. 

    The post 2 mid cap ASX shares growing strongly appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3pfNb5T

  • 5 things to watch on the ASX 200 on Thursday

    Business man watching stocks while thinking

    On Wednesday the S&P/ASX 200 Index (ASX: XJO) was in fine form and charged to new record high. The benchmark index rose 1% to 7,217.8 points.

    Will the market be able to build on this on Thursday? Here are five things to watch:

    ASX 200 expected to rise

    The Australian share market looks set to push higher again on Thursday. According to the latest SPI futures, the ASX 200 is expected to open the day 17 points or 0.25% higher this morning. This follows a mildly positive night of trade on Wall Street, which saw the Dow Jones rise 0.1%, the S&P 500 climb 0.15%, and the Nasdaq push 0.15% higher.

    Worley given conviction buy rating

    The Worley Ltd (ASX: WOR) share price could be very good value according to analysts at Goldman Sachs. This morning the broker has retained its conviction buy rating and $15.60 price target on the engineering company’s shares. It commented: “We view WOR as well positioned to capitalize on ramping sustainability spend, with our forecasts calling for green spend (ex LNG) rising to 22% of segment EBIT by 2025E.”

    Oil prices rise again

    Energy producers such as Oil Search Ltd (ASX: OSH) and Woodside Petroleum Limited (ASX: WPL) will be on watch after oil prices pushed higher again. According to Bloomberg, the WTI crude oil price is up 1.6% to US$68.77 a barrel and the Brent crude oil price has risen 1.5% to US$71.31 a barrel. OPEC’s supply discipline and growing demand is supporting prices.

    Gold price rises

    Gold miners Evolution Mining Ltd (ASX: EVN) and Resolute Mining Limited (ASX: RSG) could trade higher today after the gold price strengthened overnight. According to CNBC, the spot gold price is up 0.3% to US$1,911 an ounce. The gold price rose after US yields eased.

    Qantas refunds under scrutiny

    The Qantas Airways Limited (ASX: QAN) share price will be on watch today after rival airline Regional Express Holdings Ltd (ASX: RGS) accused it of sitting on $1 billion of customer refunds. Rex deputy chairman John Sharp is calling on Qantas to offer the same refund guarantee as it does.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

    *Returns as of May 24th 2021

    More reading

    The post 5 things to watch on the ASX 200 on Thursday appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/2RXNAxS

  • 2 growing ASX dividend shares for an income portfolio

    happy woman looking at her laptop with notes of money coming out representing financial success and a rising share price

    Are you an income investor looking for growing dividends? If you are, then you might want to look at the ASX dividend shares listed below.

    Here’s what you need to know about these shares:

    Integral Diagnostics Ltd (ASX: IDX)

    Integral Diagnostics could be a dividend share to consider. It is a medical imaging service provider that operates from a total of 72 radiology clinics. This includes 26 comprehensive sites. 

    The company employs some of Australasia’s leading radiologists and diagnostic imaging specialists in a unique medical leadership model. This model ensures quality patient care, service and access.

    Pleasingly, Integral Diagnostics has been a solid performer in FY 2021 and has been experiencing strong demand for its services. This led to the company reporting first half revenue growth of 29.5% to $170.7 million and a massive 61.1% jump in net profit after tax to $23.2 million.

    Analysts at Goldman Sachs are confident this growth will continue and expect it to underpin dividend increases in the coming years. It is forecasting dividends per share of 11.4 cents in FY 2021, 13.9 cents in FY 2022, and 15.4 cents in FY 2023.

    Based on the latest Integral Diagnostics share price of $5.07, this represents fully franked yields of 2.2%, 2.7%, and 3%, respectively.

    Rural Funds Group (ASX: RFF)

    Another ASX dividend share that is expected to grow its dividend in the coming years is Rural Funds.

    It is the owner of a $1.4 billion portfolio of diversified agricultural assets, including almond and macadamia orchards, premium vineyards, water entitlements, cattle and cropping assets.

    With Rural Funds’ properties leased to high quality tenants on long term agreements with built in rental increases, management appears confident it can grow its distribution by 4% per annum.

    This looks set to be the case in FY 2021 and FY 2022. Management has provided guidance for 11.28 cents per share this year and then 11.73 cents per share next year. This implies yields of 4.5% and 4.7%,respectively.

    These Dividend Stocks Could Be Your Next Cash Kings (FREE REPORT)

    Motley Fool Australia’s Dividend experts recently released a brand-new FREE report revealing 3 dividend stocks with JUICY franked dividends that could keep paying you meaty dividends for years to come.

    Our team of investors think these 3 dividend stocks should be a ‘must consider’ for any savvy dividend investor. But more importantly, could potentially make Australian investors a heap of passive income.

    Don’t miss out! Simply click the link below to grab your free copy and discover these 3 high conviction stocks now.

    Returns As of 15th February 2021

    More reading

    The post 2 growing ASX dividend shares for an income portfolio appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/3uP6tQK

  • 2 outstanding ASX 200 growth shares

    3D white rocket and black arrows pointing upwards

    There are a large number of growth shares to choose from on the Australian share market. So many, it can be hard to decide which ones to buy ahead of others.

    To help narrow things down, I have picked out two ASX growth shares that have been rated as buys. They are as follows:

    Domino’s Pizza Enterprises Ltd (ASX: DMP)

    The first ASX 200 growth share to look at is this pizza chain operator. Domino’s has been growing at a consistently solid rate for over a decade thanks to the popularity of its offering and the expansion of its footprint.

    The good news is that consumer tastes aren’t changing and its pizzas remain as popular as ever. The even better news is that management still sees plenty of room to grow its footprint over the next decade.

    For example, at the end of the first half, the company had a network of 2,800 stores. It is now aiming to double this over the next decade in its existing markets. Management is also looking for acquisitions and has been tipped to expand into new territories in the future. This would give the company an even larger growth runway.

    Bell Potter currently has a buy rating and $122.00 price target on the company’s shares. It notes that with a leverage ratio of 1.1x, it has $446 million in funding headroom, providing it with ample capacity to make acquisitions.

    Xero Limited (ASX: XRO)

    Another ASX 200 growth share to look at is Xero. It is a leading cloud-based business and accounting software provider with a focus on small to medium sized businesses.

    Xero recently released its full year results and reported an 18% increase in revenue to NZ$848.8 million and a 39% jump in EBITDA to NZ$191.2 million. This was underpinned by a 20% increase in subscribers during the 12 months to 2.74 million.

    This comprises ANZ subscribers of 1.56 million and International subscribers of 1.18 million. In respect to the latter, there are now 720,000 subscribers in the UK market and 285,000 in North America. While this is a large number, it is still well short of its global market opportunity. Management estimates that the cloud accounting subscriber total addressable market is 45 million.

    This gives Xero a huge runway for growth in the future, which should be bolstered by its burgeoning app ecosystem. The latter has been bolstered recently by a number of bolt on acquisitions such as Planday, Tickstar, and Waddle.

    Goldman Sachs is very positive on its future. In light of this, it recently reaffirmed its buy rating and $153.00 price target on the company’s shares.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

    *Returns as of May 24th 2021

    More reading

    The post 2 outstanding ASX 200 growth shares appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/34Em3Ed

  • Immutep (ASX:IMM) share price backtracks despite patent approval

    woman carrying out an experiment with a pipette and petri dish

    The Immutep Ltd (ASX: IMM) share price slipped today, despite the biotechnology company announcing it has secured another European patent.

    At market close, the Immutep share price finished the day 0.71%lower at 69.5 cents.

    Immutep further patent protection

    Investors appear unfazed by the company’s latest update, sending the Immutep share price lower on Wednesday.

    According to its release, Immutep has been granted its second European patent for eftilagimod alpha (efti or IMP321).

    Efti is Immutep’s lead immunotherapy candidate, and plays a vital role in the treatment of cancer and autoimmune diseases.

    Now approved by the European Patent Office, securing this latest patent further builds on the company’s intellectual property portfolio.

    Immutep received approval of the European parent patent back in November 2018. Corresponding patents for the United States followed in December 2020 and March 2021.

    Immutep CEO Marc Voigt commented on the positive outcome, saying:

    Again, this new divisional patent in Europe is very important as it specifically covers the combination of active ingredients being evaluated in many of our clinical trials, including those being reported at the upcoming ASCO 2021 Annual Meeting.

    It also highlights the critical investments we are making to protect efti which underpin further clinical development and commercialisation of this asset. Building a robust patent estate is a priority for our business and a key part of the process of bringing innovative medicines to the market to ultimately improve patient outcomes.

    The patent announced today will be active until 8 January 2036.

    About the Immutep share price

    It has been a strong 12 months for Immutep investors, with the company’s share price jumping by more than 280%. Year-to-date performance has also been pleasing, with shareholders recording gains of around 67%.

    Based on today’s share price, Immutep has a market capitalisation of roughly $484 million, ranking 438 on the ASX. The company currently has a touch over 648 million shares on its registry.

    Wondering where you should invest $1,000 right now?

    When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

    Scott just revealed what he believes could be the five best ASX stocks for investors to buy right now. These stocks are trading at near dirt-cheap prices and Scott thinks they could be great buys right now.

    *Returns as of May 24th 2021

    More reading

    The post Immutep (ASX:IMM) share price backtracks despite patent approval appeared first on The Motley Fool Australia.

    from The Motley Fool Australia https://ift.tt/34EFwVk